Video

Dr. Slovin shares her experience with CAR T-cell therapy in prostate cancer

Author(s):

Urology Times staff

Susan F. Slovin, MD, PhD, medical oncologist, associate vice chair, Academic Affairs, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses her experience with CAR T-cell therapy as an emerging treatment for patients with prostate cancer.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Refining prostate cancer therapy strategy to address RAPTOR findings
Soumyajit Roy, MS, MBBS: The effect of prostate cancer patient history in RAPTOR
1 KOL is featured in this series.
Related Content
Nivolumab plus SOC associated with improved FFBR in GG5 prostate cancer
October 11th 2024

Nivolumab plus SOC associated with improved FFBR in GG5 prostate cancer

Hannah Clarke
“Nivolumab, combined with standard of care trimodality therapy, appears to be promising for the treatment of grade group 5 prostate cancer," says John Michael Bryant, MD.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Phase 1 data show encouraging safety of 177Lu-rhPSMA-10.1 injection in mCRPC
October 9th 2024

Phase 1 data show encouraging safety of 177Lu-rhPSMA-10.1 injection in mCRPC

Hannah Clarke
"We remain on track for the opening of phase 2 in the next few months. We also expect to see the full phase 1 results presented at a scientific meeting in 2025," says David E. Gauden, DPhil.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Apalutamide associated with improved 2-year survival vs enzalutamide in mCSPC
October 2nd 2024

Apalutamide associated with improved 2-year survival vs enzalutamide in mCSPC

Hannah Clarke
At the 24-month time point, patients who received apalutamide had a 23% reduction in the risk of death compared with patients who initiated enzalutamide.
Nicolas Demogeot, MD: Impact of GETUG 14 on early-stage prostate cancer care
October 1st 2024

Nicolas Demogeot, MD: Impact of GETUG 14 on early-stage prostate cancer care

Kevin Kunzmann
Demogeot discusses his team's GETUG 14 findings regarding early administration of ADT plus high-dose radiotherapy for intermediate to high risk prostate cancer.
© 2024 MJH Life Sciences

All rights reserved.